Collaborate With CatenaBio in
Pioneering Precision
Conjugation Technology
CatenaBio’s technology is the first-ever precision conjugation reaction making use of only native amino acids. The candidates for biotherapeutic fusions range from small molecules and nucleic acids to enzymes and whole cells. If you're looking to advance your novel R&D pipeline and would like to know how CatenaBio can help you research and develop various use applications using our innovative new biotherapeutic modalities, please reach out to us.
We Partner With Top Pharmas to Advance Development of New Therapeutic Modalities
Successfully produced 25 protein-protein conjugates from 10 starting proteins.
Conjugated more than 1.5 g of product in less than 10 minutes.
Modified cell surface for improved therapeutic performance.
Conjugated to enable targeted gene delivery.
Investors
Let's Talk
Connect with us for access to our investor deck to delve deeper into our transformative program.
Message frequency may vary. You may opt out at any time. Terms and Conditions and Privacy Policy